CorMedix Total Assets Growth & History (CRMD)
CorMedix's total assets was $826.1M for fiscal 2025.
View full CorMedix company overviewCorMedix annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $826.1M | $707.3M | +595.14% |
| 2024 | 2024-12-31 | $118.8M | $36.8M | +44.83% |
| 2023 | 2023-12-31 | $82.1M | $20.0M | +32.27% |
| 2022 | 2022-12-31 | $62.0M | −$6.9M | −10.02% |
| 2021 | 2021-12-31 | $68.9M | $19.6M | +39.83% |
| 2020 | 2020-12-31 | $49.3M | $19.8M | +67.28% |
| 2019 | 2019-12-31 | $29.5M | $10.6M | +56.57% |
| 2018 | 2018-12-31 | $18.8M | $5.4M | +39.93% |
| 2017 | 2017-12-31 | $13.5M | −$8.5M | −38.58% |
| 2016 | 2016-12-31 | $21.9M | −$15.2M | −40.96% |
| 2015 | 2015-12-31 | $37.1M | $32.0M | +627.80% |
| 2014 | 2014-12-31 | $5.1M | $2.1M | +71.77% |
| 2013 | 2013-12-31 | $3.0M | $1.8M | +157.34% |
| 2012 | 2012-12-31 | $1.2M | −$1.4M | −54.88% |
| 2011 | 2011-12-31 | $2.6M | −$6.3M | −71.11% |
| 2010 | 2010-12-31 | $8.8M | — | — |
CorMedix quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $904.1M | $651.5M | +257.90% |
| Q1 2026 | 2026-03-31 | $815.6M | $666.1M | +445.27% |
| Q4 2025 | 2025-12-31 | $826.1M | $707.3M | +595.14% |
| Q3 2025 | 2025-09-30 | $750.9M | $673.3M | +867.78% |
| Q2 2025 | 2025-06-30 | $252.6M | $194.9M | +337.55% |
| Q1 2025 | 2025-03-31 | $149.6M | $81.6M | +119.90% |
| Q4 2024 | 2024-12-31 | $118.8M | $36.8M | +44.83% |
| Q3 2024 | 2024-09-30 | $77.6M | −$13.8M | −15.14% |
| Q2 2024 | 2024-06-30 | $57.7M | $697,814 | +1.22% |
| Q1 2024 | 2024-03-31 | $68.0M | $8.8M | +14.84% |
| Q4 2023 | 2023-12-31 | $82.1M | $20.0M | +32.27% |
| Q3 2023 | 2023-09-30 | $91.4M | $29.4M | +47.28% |
| Q2 2023 | 2023-06-30 | $57.0M | −$10.7M | −15.82% |
| Q1 2023 | 2023-03-31 | $59.2M | −$5.7M | −8.78% |
| Q4 2022 | 2022-12-31 | $62.0M | −$6.9M | −10.02% |
| Q3 2022 | 2022-09-30 | $62.1M | −$13.3M | −17.66% |
| Q2 2022 | 2022-06-30 | $67.7M | −$13.1M | −16.21% |
| Q1 2022 | 2022-03-31 | $64.9M | −$19.3M | −22.94% |
| Q4 2021 | 2021-12-31 | $68.9M | $19.6M | +39.83% |
| Q3 2021 | 2021-09-30 | $75.4M | $35.4M | +88.37% |
| Q2 2021 | 2021-06-30 | $80.9M | $56.6M | +233.61% |
| Q1 2021 | 2021-03-31 | $84.3M | $56.9M | +207.52% |
| Q4 2020 | 2020-12-31 | $49.3M | $19.8M | +67.28% |
| Q3 2020 | 2020-09-30 | $40.0M | $6.3M | +18.70% |
| Q2 2020 | 2020-06-30 | $24.2M | −$3.3M | −12.05% |
| Q1 2020 | 2020-03-31 | $27.4M | $91,469 | +0.33% |
| Q4 2019 | 2019-12-31 | $29.5M | $10.6M | +56.57% |
| Q3 2019 | 2019-09-30 | $33.7M | $25.7M | +318.92% |
| Q2 2019 | 2019-06-30 | $27.6M | $21.6M | +365.01% |
| Q1 2019 | 2019-03-31 | $27.3M | $17.7M | +184.20% |
| Q4 2018 | 2018-12-31 | $18.8M | $5.4M | +39.93% |
| Q3 2018 | 2018-09-30 | $8.0M | −$5.9M | −42.22% |
| Q2 2018 | 2018-06-30 | $5.9M | −$15.2M | −71.99% |
| Q1 2018 | 2018-03-31 | $9.6M | −$5.3M | −35.65% |
| Q4 2017 | 2017-12-31 | $13.5M | −$8.5M | −38.58% |
| Q3 2017 | 2017-09-30 | $13.9M | −$14.9M | −51.70% |
| Q2 2017 | 2017-06-30 | $21.2M | −$10.1M | −32.22% |
| Q1 2017 | 2017-03-31 | $14.9M | −$18.7M | −55.57% |
| Q4 2016 | 2016-12-31 | $21.9M | −$15.2M | −40.96% |
| Q3 2016 | 2016-09-30 | $28.8M | −$10.5M | −26.63% |
| Q2 2016 | 2016-06-30 | $31.2M | −$7.6M | −19.55% |
| Q1 2016 | 2016-03-31 | $33.6M | $23.9M | +244.65% |
| Q4 2015 | 2015-12-31 | $37.1M | $32.0M | +627.80% |
| Q3 2015 | 2015-09-30 | $39.3M | $32.5M | +474.23% |
| Q2 2015 | 2015-06-30 | $38.8M | $30.5M | +369.94% |
| Q1 2015 | 2015-03-31 | $9.8M | −$9,583 | −0.10% |
| Q4 2014 | 2014-12-31 | $5.1M | $2.1M | +71.77% |
| Q3 2014 | 2014-09-30 | $6.8M | $5.8M | +560.24% |
| Q2 2014 | 2014-06-30 | $8.3M | $7.9M | +1989.55% |
| Q1 2014 | 2014-03-31 | $9.8M | $8.8M | +908.77% |
| Q4 2013 | 2013-12-31 | $3.0M | $1.8M | +157.34% |
| Q3 2013 | 2013-09-30 | $1.0M | −$220,685 | −17.55% |
| Q2 2013 | 2013-06-30 | $395,085 | −$641,248 | −61.88% |
| Q1 2013 | 2013-03-31 | $967,649 | −$1.1M | −52.46% |
| Q4 2012 | 2012-12-31 | $1.2M | −$1.4M | −54.88% |
| Q3 2012 | 2012-09-30 | $1.3M | −$1.8M | −58.51% |
| Q2 2012 | 2012-06-30 | $1.0M | −$3.9M | −79.06% |
| Q1 2012 | 2012-03-31 | $2.0M | — | — |
| Q4 2011 | 2011-12-31 | $2.6M | −$6.3M | −71.11% |
| Q3 2011 | 2011-09-30 | $3.0M | — | — |
| Q2 2011 | 2011-06-30 | $4.9M | — | — |
| Q4 2010 | 2010-12-31 | $8.8M | — | — |
CorMedix total assets trends
Over the last five fiscal years, CorMedix's total assets increased from $49.3M to $826.1M, a change of $776.8M. The latest reported quarter, Q2 2026, shows $904.1M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CorMedix source filings ↗